2.50
Hdl Handle:
http://hdl.handle.net/10541/88004
Title:
Paclitaxel: a hope for advanced non-small cell lung cancer?
Authors:
Ranson, Malcolm R; Thatcher, Nick
Abstract:
Recent studies have shown that paclitaxel (Taxol); Bristol-Myers Squibb Co., Princeton, NJ) is an active agent in the treatment of advanced non-small cell lung cancer (NSCLC). Early trials in patients with advanced NSCLC utilised a 24 h infusion schedule and reported objective tumour responses in 21 - 24% of patients. Shorter infusion schedules have equivalent efficacy, and combined results from 14 separate trials of single agent paclitaxel in advanced NSCLC show an overall tumour response rate of 26%. Alternative schedules of paclitaxel from the traditional regimen every three weeks are under active investigation, but it is premature to assess whether these will yield improved efficacy for patients with advanced NSCLC. A single multicentre randomised trial of paclitaxel versus best supportive care in advanced NSCLC showed a significant survival advantage for the chemotherapy arm. Two large randomised Phase III trials have shown that paclitaxel and cisplatin is modestly more effective than cisplatin and podophyllotoxin combinations. The addition of cisplatin or carboplatin to paclitaxel results in higher response rates than for each of the drugs as single agents, but it is unclear whether the combinations yield superior survival or quality of life compared to single agent paclitaxel, or to other paclitaxel-containing regimens.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK. malcolm.ranson@man.ac.uk
Citation:
Paclitaxel: a hope for advanced non-small cell lung cancer? 1999, 8 (6):837-48 Expert Opin Investig Drugs
Journal:
Expert Opinion on Investigational Drugs
Issue Date:
Jun-1999
URI:
http://hdl.handle.net/10541/88004
DOI:
10.1517/13543784.8.6.837
PubMed ID:
15992134
Type:
Article
Language:
en
ISSN:
1744-7658
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRanson, Malcolm Ren
dc.contributor.authorThatcher, Nicken
dc.date.accessioned2009-12-15T15:57:06Z-
dc.date.available2009-12-15T15:57:06Z-
dc.date.issued1999-06-
dc.identifier.citationPaclitaxel: a hope for advanced non-small cell lung cancer? 1999, 8 (6):837-48 Expert Opin Investig Drugsen
dc.identifier.issn1744-7658-
dc.identifier.pmid15992134-
dc.identifier.doi10.1517/13543784.8.6.837-
dc.identifier.urihttp://hdl.handle.net/10541/88004-
dc.description.abstractRecent studies have shown that paclitaxel (Taxol); Bristol-Myers Squibb Co., Princeton, NJ) is an active agent in the treatment of advanced non-small cell lung cancer (NSCLC). Early trials in patients with advanced NSCLC utilised a 24 h infusion schedule and reported objective tumour responses in 21 - 24% of patients. Shorter infusion schedules have equivalent efficacy, and combined results from 14 separate trials of single agent paclitaxel in advanced NSCLC show an overall tumour response rate of 26%. Alternative schedules of paclitaxel from the traditional regimen every three weeks are under active investigation, but it is premature to assess whether these will yield improved efficacy for patients with advanced NSCLC. A single multicentre randomised trial of paclitaxel versus best supportive care in advanced NSCLC showed a significant survival advantage for the chemotherapy arm. Two large randomised Phase III trials have shown that paclitaxel and cisplatin is modestly more effective than cisplatin and podophyllotoxin combinations. The addition of cisplatin or carboplatin to paclitaxel results in higher response rates than for each of the drugs as single agents, but it is unclear whether the combinations yield superior survival or quality of life compared to single agent paclitaxel, or to other paclitaxel-containing regimens.en
dc.language.isoenen
dc.subjectChemotherapyen
dc.subjectNon-Small-Cell Lung Canceren
dc.subjectPaclitaxelen
dc.titlePaclitaxel: a hope for advanced non-small cell lung cancer?en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK. malcolm.ranson@man.ac.uken
dc.identifier.journalExpert Opinion on Investigational Drugsen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.